Luprolide Acetate (Lupron®, Eligard®)

BCommon name: Luprolide Acetate
Brand name: Lupron®, Eligard®
 

What is Luprolide Acetate?

Luprolide Acetate is a hormonal therapy medication that is used in the palliative treatment of advanced prostate cancer. It works by slowing or stopping the production of testosterone to stop or slow prostate cancer cells from growing and reproducing.
 

How is Luprolide Acetate administered?

Luprolide Acetate is administered by subcutaneous injection.
 

What are possible side effects of this treatment?

Everyone responds differently to hormone therapy – some experience many side effects while others experience very few. Below are some side effects experienced by those who received luprolide acetate. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
  • Breast tenderness
  • Decreased libido
  • Diarrhea
  • Fatigue
  • Headaches
  • Hot flashes
  • Impotence (erectile dysfunction)
  • Nausea / vomiting
  • Osteoporosis (weakened bones)
  • Weight gain
 

 Is Luprolide Acetate covered in my province or territory?*

Luprolide acetate (Eligard®) is covered by all provincial/territorial drug programs.

​Luprolide acetate (Lupron®​) is covered by provincial drug programs in:
  • Alberta​
  • British Columbia
  • Manitoba
  • New Brunswick
  • Newfoundland & Labrador
  • Nova Scotia
  • Quebec
  • Saskatchewan
​Luprolide acetate (Lupron®) is not covered by provincial drug programs in:
  • Northwest Territories
  • Nunavut
  • Ontario
  • Prince Edward Island
  • Yukon

Last Reviewed: July 2017

Help us take the first steps toward prevention. Donate Now




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Do men’s toenails contain clues about prostate cancer prevention?

Toronto, January 29, 2018 – Funded by Prostate Cancer Canada (PCC), Dr.
More

Discovery of a promising new medication to block 'master key' of cancer growth

Vancouver, BC – For years, researchers have investigated approaches to prevent cancer-causing cells from multiplying in the body.
More

RFP: Content Development and Delivery of an Accredited Electronic Continuing Medical Education Course for Prostate Cancer Specialists

Prostate Cancer Canada invites applications from service providers interested in the development, promotion and delivery of an accredited electronic Continuing Medical Education course targeting prostate cancer specialists, including urologists.
More


Click here for news archive